Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Australian Pension Funds Boost Currency Hedging as Aussie Dollar Strengthens 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Medipost Co. Ltd, a South Korean biotechnology company, purchased a stake in Canada's OmniaBio Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM), as it is planning to launch its own contract development and manufacturing organization (CDMO) business in North America.
Medipost Co. is planning to make new stem cell treatment products at OmniaBio's facilities in Canada. Thus, it entered into a strategic agreement with the company that is currently a leader in stem cell therapeutics in the world.
The Korean firm engages in the development and manufacturing of stem cell biotech products, and it has acquired a 39.6% stake in OmniaBio Inc. Mediapost is putting in an investment of ₩29.5 billion or around $30 million in Canadian dollars for the purchase. The acquisition deal is set to close on July 1.
According to The Korea Economic Daily, Medipost will be establishing its CDMO business in North America after the deal is completed. It is also planning to raise its stake in OmniaBio by buying convertible bonds worth ₩59.1 billion, and the company is hoping to achieve this by the end of 2024.
With the given numbers, Medipost is set to become the Canadian CDMO firm's largest shareholder, with the total investment reaching C$90 million. OmniaBio's facility is located in Hamilton, Ontario, and it is currently working on a project to expand its facilities for cell and gene therapies from 8,500 square meters to 10,000 square meters site by the year 2025.
"CCRM has spent a great deal of time looking for the right investment partner for OmniaBio, and we are very pleased to have Medipost on board," OmniBio's president, Mitchel Sivilotti, said in a press release. "Medipost will be an initial anchor and revenue generating customer of OmniaBio and will also help us develop an international customer base in Asia. We are launching from a strong and stable position and will be starting construction at McMaster Innovation Park this summer."
Finally, it was revealed that the money from Medipost's purchase deal will be used for the real estate construction and operation of OmniaBio. The overall project was said to be worth $580 million.
